|
gptkbp:instanceOf
|
gptkb:anticoagulant
gptkb:direct_thrombin_inhibitor
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2008
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
6.5%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211914-51-1
|
|
gptkbp:category
|
DOAC (direct oral anticoagulant)
NOAC (novel oral anticoagulant)
|
|
gptkbp:contraindication
|
gptkb:mechanical_heart_valve
active pathological bleeding
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:discoveredBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
capsule
150 mg
75 mg
110 mg
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
gptkbp:interactsWith
|
gptkb:rifampin
gptkb:ketoconazole
P-glycoprotein inhibitors
|
|
gptkbp:KEGGID
|
D08141
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
direct inhibition of thrombin (factor IIa)
|
|
gptkbp:MedlinePlusID
|
a610024
|
|
gptkbp:metabolism
|
not metabolized by CYP450
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:PubChem_CID
|
448119
CHEMBL1175
DB06695
|
|
gptkbp:riskFactor
|
not recommended in patients with prosthetic heart valves
risk of spinal/epidural hematoma with neuraxial anesthesia
increased risk of bleeding with P-gp inhibitors
may cause dyspepsia
not recommended in severe renal impairment
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:UNII
|
2XTZ996338
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:NOAC
gptkb:CYP3A4
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
dabigatran
|